Phase 2 N=77 Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome
Obesity · Metabolic Disease
Primary: Change in Insulin Sensitivity From FSIVGTT — 0.20; 0.41; -0.45 10^-5*min^-1*mU^-1*mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=71 Study of Fruquintinib in Patients With Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Progression Free Survival (PFS) — 4.731; 0.986 months
Phase 2 N=40 Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis
Dermatitis, Atopic
Primary: Change From Baseline in Lesion Total Sign Score (TSS) for Target Lesions Treated With Crisaborole Ointment 2% or Vehicle at Day 15 — -4.5; -2.1 units on a scale…
Phase 2 N=39 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma
Neuroblastoma
Primary: Assess the Impact of High-dose 3F8/GM-CSF
Phase 2 N=14 Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Overall Response Rate — 6; 7 Participants
Phase 2 N=17 Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?
Smoking
Primary: Latency — 24.56; 26.64 minutes
Phase 2 N=14 Effect of Intranasal Insulin on LH Concentrations in Man
Hypogonadotropic Hypogonadism
Primary: LH — 7.7; 3.3; 7.9; 3.8 IU/L
Phase 2 N=25 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung
KIF5B-RET-Positive Adenocarcinoma of the Lung
Primary: Objective Response Rate (ORR) — 16.0 percentage of participants
Phase 2 N=40 Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant
CD20 Positive · Hematopoietic and Lymphoid Cell Neoplasm · Lymphocytic Neoplasm
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants
Phase 2 N=55 Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Breast Cancer
Primary: Phase I Portion: Maximum Tolerated Dose/MTD of Dasatinib When Administered in Combination With a Fixed Dose of Weekly Paclitaxel. — 120 mg of dasatinib
Phase 2 N=13 Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
Cutaneous T Cell Lymphoma
Primary: The Number of Participants That Tolerated the Maximum Drug Dose — 8; 4 Participants
Phase 2 N=31 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
Neuroblastoma
Primary: Assess the Activity of High-dose 3F8/GM-CSF
Phase 2 N=18 Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
Anaplastic Astrocytoma · Brain Stem Glioma · Childhood Mixed Glioma
Primary: Maximum-tolerated Dose of Veliparib Defined as Highest Dose Level With Fewer Than 2 Dose Limiting Toxicities in 6 Patients as Assessed by the National Cancer Institute…
Phase 2 N=71 Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
Optic Neuritis
Primary: Retinal Ganglion Cell Inner Plexiform Layer Thickness — 36.56; 34.65; 31; 29.42 micron
Phase 2 N=88 Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease
Alzheimer's Disease
Primary: Changes in Cerebrospinal Fluid (CSF) Beta-amyloid-42 Levels Compared to Baseline as Measured by xMAP — 1.01; 0.98 ratio